Furthermore, the M1 muscarinic agonist AF102B known as Cevimeline, previously prescribed in the treatment of dry mouth in SS, can reduce the β-amyloid peptide level and its inhibition as well as the enhanced secretion of APP. This evidence concerns the gene APP and synovial sarcoma.